Stone X Group Inc. Edwards Lifesciences Corp Transaction History

Stone X Group Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2025	BUY	$84.3 - $94.31 $590,521 - $660,641	7,005 New	7,005 $647 Million
Q1 2024 Aug 13, 2025	BUY	$72.54 - $95.56 $83,348 - $109,798	1,149 Added 20.04%	6,883 $658 Million
Q4 2023 Aug 13, 2025	BUY	$61.71 - $77.76 $353,845 - $445,875	5,734 New	5,734 $437 Million
Q3 2023 Aug 13, 2025	BUY	$69.28 - $93.38 $63,460 - $85,536	916 Added 32.61%	3,725 $258 Million
Q2 2023 Aug 13, 2025	BUY	$81.41 - $94.33 $228,680 - $264,972	2,809 New	2,809 $265 Million

Q1 2023 Aug 13, 2025	BUY	$74.26 - $84.51 $199,685 - $227,247	2,689 New	2,689 $222 Million
Q2 2022 Aug 13, 2025	SELL	$86.5 - $128.27 $70,065 - $103,898	-810 Reduced 22.95%	2,719 $259 Million
Q1 2022 Aug 13, 2025	BUY	$101.96 - $128.34 $359,816 - $452,911	3,529 New	3,529 $415 Million

1,459

467M

3.46M

4.07M

Ticker EW
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 618,259,968
Market Cap $53.4B
Description
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair...

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

Stay updated on Stone X Group Inc. with notifications on news.